Analysts Issue Forecasts for Chemours’ Q4 Earnings (NYSE:CC)

The Chemours Company (NYSE:CC) – Zacks Research reduced their Q4 2024 earnings per share estimates for Chemours in a research note issued on Tuesday, January 14th. Zacks Research analyst R. Department now expects that the specialty chemicals company will post earnings per share of $0.10 for the quarter, down from their prior forecast of $0.18. The consensus estimate for Chemours’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Chemours’ Q1 2025 earnings at $0.51 EPS, Q4 2025 earnings at $0.16 EPS, FY2025 earnings at $2.01 EPS, Q2 2026 earnings at $0.78 EPS, Q3 2026 earnings at $0.61 EPS, Q4 2026 earnings at $0.42 EPS and FY2026 earnings at $2.43 EPS.

Chemours (NYSE:CC) last announced its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The firm had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.44 billion. During the same quarter in the previous year, the firm posted $0.64 EPS. The company’s revenue for the quarter was up .9% compared to the same quarter last year.

Several other equities research analysts have also weighed in on the company. Royal Bank of Canada restated an “outperform” rating and set a $25.00 price target on shares of Chemours in a research report on Thursday, December 12th. Barclays upped their target price on shares of Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Morgan Stanley dropped their price objective on shares of Chemours from $25.00 to $22.00 and set an “equal weight” rating on the stock in a research note on Monday. BMO Capital Markets raised their target price on shares of Chemours from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, October 7th. Finally, The Goldman Sachs Group dropped their price target on Chemours from $24.00 to $21.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 7th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Chemours presently has an average rating of “Hold” and an average price target of $23.75.

Chemours Stock Up 0.9 %

CC stock opened at $18.79 on Thursday. Chemours has a fifty-two week low of $15.10 and a fifty-two week high of $32.48. The company has a market capitalization of $2.81 billion, a price-to-earnings ratio of 37.58 and a beta of 1.83. The business’s 50 day moving average price is $19.21 and its two-hundred day moving average price is $19.80. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73.

Institutional Trading of Chemours

A number of hedge funds and other institutional investors have recently bought and sold shares of CC. Quantbot Technologies LP grew its stake in shares of Chemours by 119.6% during the 2nd quarter. Quantbot Technologies LP now owns 122,973 shares of the specialty chemicals company’s stock valued at $2,776,000 after acquiring an additional 66,966 shares during the period. Renaissance Technologies LLC purchased a new position in Chemours in the 2nd quarter worth approximately $2,480,000. Vanguard Personalized Indexing Management LLC lifted its holdings in Chemours by 14.7% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 14,102 shares of the specialty chemicals company’s stock worth $318,000 after purchasing an additional 1,803 shares in the last quarter. Seven Eight Capital LP bought a new position in Chemours in the 2nd quarter worth approximately $2,657,000. Finally, XTX Topco Ltd grew its holdings in Chemours by 122.2% during the 2nd quarter. XTX Topco Ltd now owns 26,794 shares of the specialty chemicals company’s stock valued at $605,000 after buying an additional 14,735 shares in the last quarter. Hedge funds and other institutional investors own 76.26% of the company’s stock.

Insider Buying and Selling

In other news, SVP Alvenia Scarborough sold 7,500 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total value of $154,800.00. Following the completion of the sale, the senior vice president now directly owns 16,645 shares in the company, valued at $343,552.80. This represents a 31.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.47% of the stock is owned by corporate insiders.

Chemours Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Friday, November 15th were given a dividend of $0.25 per share. The ex-dividend date was Friday, November 15th. This represents a $1.00 annualized dividend and a dividend yield of 5.32%. Chemours’s dividend payout ratio (DPR) is presently 200.00%.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.